Natera is facing a class action lawsuit in the Northern District of California alleging misleading advertising and marketing claims around its preimplantation genetic test for aneuploidy (Spectrum PGT-A). Plaintiffs Melissa Klein and Valerie Griffeth argue Natera promoted the test as “proven, accurate, and reliable” for reducing miscarriage risk and improving healthy-baby outcomes despite disputed scientific support. The filing alleges PGT-A was marketed as an IVF add-on to improve implantation, miscarriage rates, time to pregnancy, and live birth rates. Plaintiffs also cite studies and professional guidance indicating that the value of PGT-A as a screening test has not been definitively established. Natera reportedly discontinued Spectrum PGT-A before the filing, but the suit still targets past marketing behavior. For reproductive-health diagnostics, the case adds litigation risk around claims substantiation and how test performance is communicated to consumers and payers.